Literature DB >> 9078276

CGP 48664, a potent and specific S-adenosylmethionine decarboxylase inhibitor: effects on regulation and stability of the enzyme.

F Svensson1, H Mett, L Persson.   

Abstract

Mammalian S-adenosylmethionine decarboxylase (AdoMetDC) catalyses a regulatory important step in the biosynthesis of polyamines and is a potential target for therapeutic agents against various parasitic diseases and proliferative disorders. In the present study we examined the effects of a newly synthesized AdoMetDC inhibitor. 4-amidinoindan-1-one 2'-amidinohydrazone (CGP 48664), on polyamine metabolism in the mouse leukaemia cell line L1210. Treatment of the cells with 2 microM CGP 48664 led to a depletion of cellular spermidine and spermine. The putrescine content, in contrast, was markedly increased. Cells seeded in the presence of the inhibitor showed a significant decrease in growth rate, which was fully reversed by the addition of 2 microM spermidine or 1 microM spermine. The syntheses of ornithine decarboxylase and AdoMetDC were greatly increased in cells treated with CGP 48664. These increases were not correlated with similar changes in the mRNA levels, indicating the involvement of a translational mechanism. CGP 48664 was demonstrated to be a very poor competitor of spermidine uptake in the L1210 cells. L1210 cells deficient in polyamine transport were as sensitive to the antiproliferative effect of the inhibitor as were the parental cells, indicating that CGP 48664 did not enter the cells by the polyamine transport system. In addition to inhibiting AdoMetDC, CGP 48664 stabilized the enzyme against degradation. In the present study we also demonstrated that aminoguanidine (AMG), which is frequently used in cellular systems to inhibit any action of serum polyamine oxidase, apparently inhibits AdoMetDC by an irreversible mechanism that markedly stabilizes the enzyme against proteolytic degradation. CGP 48664 and the parental compound methylglyoxal bis(guanylhydrazone), which is also a potent inhibitor of AdoMetDC, contain one or two AMG-like moieties; the importance of these residues in the inhibition of AdoMetDC is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9078276      PMCID: PMC1218191          DOI: 10.1042/bj3220297

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Inhibition of diamine oxidase by 1,1-[(methylethanediylidene)-dinitrilo]-bis-(3-aminoguanidine) and 1,1'-[(methylethanediylidene)-dinitrilo]-diguanidine.

Authors:  A E Pegg; S M McGill
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

2.  Paradoxical enhancement of S-adenosylmethionine decarboxylase in rat tissues following administration of the specific inhibitor methyl glyoxal bis(guanylhydrazone).

Authors:  A E Pegg; A Corti; H G Williams-Ashman
Journal:  Biochem Biophys Res Commun       Date:  1973-05-15       Impact factor: 3.575

3.  Stimulation of the decarboxylation of S-adenosylmethionine by putrescine in mammalian tissues.

Authors:  A E Pegg; H G Williams-Ashman
Journal:  Biochem Biophys Res Commun       Date:  1968-01-11       Impact factor: 3.575

4.  Identification of pyruvate in S-adenosylmethionine decarboxylase from rat liver.

Authors:  A A Demetriou; M S Cohn; C W Tabor; H Tabor
Journal:  J Biol Chem       Date:  1978-03-10       Impact factor: 5.157

5.  Evidence for the presence of pyruvate in rat liver S-adenosylmethionine decarboxylase.

Authors:  A E Pegg
Journal:  FEBS Lett       Date:  1977-12-01       Impact factor: 4.124

Review 6.  Polyamines as targets for therapeutic intervention.

Authors:  L J Marton; A E Pegg
Journal:  Annu Rev Pharmacol Toxicol       Date:  1995       Impact factor: 13.820

7.  Antibodies to ornithine decarboxylase. Immunochemical cross-reactivity.

Authors:  L Persson
Journal:  Acta Chem Scand B       Date:  1982

8.  Increased survival of L1210 leukemic mice by prevention of the utilization of extracellular polyamines. Studies using a polyamine-uptake mutant, antibiotics and a polyamine-deficient diet.

Authors:  A Ask; L Persson; O Heby
Journal:  Cancer Lett       Date:  1992-09-14       Impact factor: 8.679

Review 9.  Ornithine decarboxylase as an enzyme target for therapy.

Authors:  P P McCann; A E Pegg
Journal:  Pharmacol Ther       Date:  1992       Impact factor: 12.310

10.  Cytostasis induced in L1210 murine leukaemia cells by the S-adenosyl-L-methionine decarboxylase inhibitor 5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxyadenosine may be due to hypusine depletion.

Authors:  T L Byers; B Ganem; A E Pegg
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

View more
  4 in total

1.  Cystathionine γ-lyase exacerbates Helicobacter pylori immunopathogenesis by promoting macrophage metabolic remodeling and activation.

Authors:  Yvonne L Latour; Johanna C Sierra; Jordan L Finley; Mohammad Asim; Daniel P Barry; Margaret M Allaman; Thaddeus M Smith; Kara M McNamara; Paula B Luis; Claus Schneider; Justin Jacobse; Jeremy A Goettel; M Wade Calcutt; Kristie L Rose; Kevin L Schey; Ginger L Milne; Alberto G Delgado; M Blanca Piazuelo; Bindu D Paul; Solomon H Snyder; Alain P Gobert; Keith T Wilson
Journal:  JCI Insight       Date:  2022-06-22

2.  Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.

Authors:  Dana-Lynn T Koomoa; Lisette P Yco; Tamas Borsics; Christopher J Wallick; André S Bachmann
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

3.  Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma.

Authors:  Dana-Lynn T Koomoa; Tamas Borsics; David J Feith; Craig C Coleman; Christopher J Wallick; Ivonne Gamper; Anthony E Pegg; André S Bachmann
Journal:  Mol Cancer Ther       Date:  2009-07-07       Impact factor: 6.261

4.  A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.

Authors:  R Paridaens; D R Uges; N Barbet; L Choi; M Seeghers; W T van der Graaf; H J Groen; H Dumez; I V Buuren; F Muskiet; R Capdeville; A T Oosterom; E G de Vries
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.